Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples